Ryan Weispfenning | VP, IR |
Geoffrey Martha | Chairman & CEO |
Karen Parkhill | CFO |
Brad Welnick | IR |
Que Dallara | EVP & President, Diabetes Operating Unit |
Sean Salmon | EVP & President, Cardiovascular Portfolio |
Brett Wall | EVP & President, Neuroscience Portfolio |
Bob White | EVP & President, Medical Surgical Portfolio |
Robert Marcus | JPMorgan |
Vijay Kumar | Evercore ISI |
Larry Biegelsen | Wells Fargo |
Matt Miksic | Barclays |
Travis Steed | BofA |
Matt O'Brien | Piper Sandler Companies |
Peter Chickering | Deutsche Bank |
Matt Taylor | Jefferies |
Shagun Singh | RBC |
Rich Newitter | Truist Securities |
Joanne Wuensch | Citi |
Anthony Petrone | Mizuho Securities |
Good morning, I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations. Welcome to Minnesota, land of 10,000 lakes. I appreciate that you're joining us today for Medtronic's Fiscal Year 2023 Fourth Quarter Earnings Video Webcast.
Before we go inside to hear our prepared remarks, I'll share a few details about today's webcast.
Joining me are Geoff Martha, Medtronic Chairman and Chief Executive Officer; and Karen Parkhill, Medtronic Chief Financial Officer; Jeff and Karen will provide comments on the results of our fourth quarter and fiscal year 2023, which ended on April 28, 2023 and our outlook for fiscal year '24.